EGFR and non-small cell lung carcinoma: In addition, it was recently approved as a first-line treatment for adults with PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) without EGFR (epidermal growth factor receptor) mutations or with ALK (anaplastic lymphoma kinase)-negative NSCLC.